Cargando…
Mitochondrial modulation with leriglitazone as a potential treatment for Rett syndrome
BACKGROUND: Rett syndrome is a neuropediatric disease occurring due to mutations in MECP2 and characterized by a regression in the neuronal development following a normal postnatal growth, which results in the loss of acquired capabilities such as speech or purposeful usage of hands. While altered n...
Autores principales: | Musokhranova, Uliana, Grau, Cristina, Vergara, Cristina, Rodríguez-Pascau, Laura, Xiol, Clara, Castells, Alba A., Alcántara, Soledad, Rodríguez-Pombo, Pilar, Pizcueta, Pilar, Martinell, Marc, García-Cazorla, Angels, Oyarzábal, Alfonso |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601217/ https://www.ncbi.nlm.nih.gov/pubmed/37884937 http://dx.doi.org/10.1186/s12967-023-04622-5 |
Ejemplares similares
-
Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate
por: Pizcueta, Pilar, et al.
Publicado: (2023) -
PPAR Gamma Agonist Leriglitazone Recovers Alterations Due to Pank2-Deficiency in hiPS-Derived Astrocytes
por: Santambrogio, Paolo, et al.
Publicado: (2023) -
Comprehensive Analysis of GABA(A)-A1R Developmental Alterations in Rett Syndrome: Setting the Focus for Therapeutic Targets in the Time Frame of the Disease
por: Oyarzabal, Alfonso, et al.
Publicado: (2020) -
Technological Improvements in the Genetic Diagnosis of Rett Syndrome Spectrum Disorders
por: Xiol, Clara, et al.
Publicado: (2021) -
Energy metabolism in childhood neurodevelopmental disorders
por: A, Oyarzábal, et al.
Publicado: (2021)